Other Clinical Trial - Validation of a Urine-based Assay With Genomic

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04736394` - A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients	Phase 3
Recruiting	`NCT05951179` - Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer	Phase 2
Active, not recruiting	`NCT04943094` - Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
Not yet recruiting	`NCT06227065` - Precise Neoadjuvant Chemoresection of Low Grade NMIBC	Phase 2
Completed	`NCT01458847` - Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer	Phase 1
Recruiting	`NCT03914794` - A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors	Phase 2
Recruiting	`NCT05126472` - Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment	Phase 1
Recruiting	`NCT04644835` - Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer	N/A
Recruiting	`NCT06126796` - Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Active, not recruiting	`NCT04100733` - Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor	N/A
Recruiting	`NCT05085990` - Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer	Phase 1
Recruiting	`NCT03560479` - A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer	Phase 1/Phase 2
Terminated	`NCT01310803` - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder	Phase 3
Completed	`NCT03081858` - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Phase 1/Phase 2
Completed	`NCT04498702` - Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy	Phase 2
Recruiting	`NCT05337397` - Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Active, not recruiting	`NCT04490993` - Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients	Phase 3
Recruiting	`NCT04859751` - Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer	Phase 3
Recruiting	`NCT05672615` - Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Not yet recruiting	`NCT06245603` - A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer	N/A

NCT number	NCT02969109
Study type	Observational
Source	Genomic Health®, Inc.
Contact
Status	Completed
Phase
Start date	October 2015
Completion date	September 18, 2018

Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms